Related Experiment Video
Updated: May 6, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis
Abstract:
Multiple sclerosis (MS) is a progressive inflammatory disease with several possible clinical courses; before the development of definite MS, some patients may have clinically isolated syndrome (CIS), which is a single attack of neurological symptoms caused by inflammation or demyelination. Disease-modifying treatments (DMTs) have been extensively used for the management of MS, resulting in improvements in the clinical presentation and decreases in MS-associated neurological damage. Earlier initiation of DMT in the course of MS is associated with better outcomes. For patients with CIS, initiation of interferon-beta or glatiramer acetate treatment after an initial clinical event indicative of MS has been associated with delays in the progression to clinically definite MS as well as improvements in measures of neurological damage via magnetic resonance imaging. The initiation of treatment for patients with CIS should be considered, and nurses play a vital role in educating patients about the risks of conversion to MS and the benefits of early DMT.
Insights
Early treatment for clinically isolated syndrome (CIS) with disease-modifying therapies (DMTs) can delay multiple sclerosis (MS) progression. Nurses are key in educating patients on early DMT benefits for better outcomes.
Area of Science:
- Neuroimmunology
- Neurology
- Clinical Therapeutics
Background:
- Multiple sclerosis (MS) is a progressive inflammatory demyelinating disease.
- Clinically isolated syndrome (CIS) may precede definite MS.
- Disease-modifying treatments (DMTs) improve MS clinical presentation and reduce neurological damage.
Purpose of the Study:
- To evaluate the impact of early DMT initiation in patients with CIS.
- To assess the role of nurses in patient education regarding early treatment.
Main Methods:
- Review of existing literature on DMTs for CIS.
- Analysis of treatment effects on delaying conversion to definite MS.
- Assessment of MRI-based neurological damage markers.
Main Results:
- Initiating interferon-beta or glatiramer acetate in CIS patients delays conversion to definite MS.
- Early DMTs show improvements in neurological damage measures on MRI.
- Patient education by nurses is crucial for treatment adherence and understanding.
Conclusions:
- Early initiation of DMT for CIS is recommended.
- Nurses play a vital role in patient counseling regarding early intervention benefits.
- Prompt treatment can significantly alter the disease course and improve patient outcomes.
More Related Videos
Related Concept Videos
Multiple Sclerosis l: Introduction
Secondary Spinal Cord Injury llI: Pathophysiology
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

